Patents by Inventor Luiz Belardinelli

Luiz Belardinelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION
    Publication number: 20140275098
    Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.
    Type: Application
    Filed: November 13, 2013
    Publication date: September 18, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Luiz Belardinelli, Hunter Campbell Gillies, Faquan Liang, John Shryock, Suya Yang
  • METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20140243358
    Abstract: The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Application
    Filed: October 4, 2013
    Publication date: August 28, 2014
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Luiz Belardinelli, Dewan Zeng, Hongyan Zhong
  • SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION
    Publication number: 20140221286
    Abstract: It is discovered that sodium-channel blockers inhibit the secretion of glucagon from pancreatic alpha cells. The present disclosure, based on such discoveries, provides compositions and methods for the treatment of hyperglycemia and related diseases and conditions with Na-channel blockers.
    Type: Application
    Filed: September 20, 2012
    Publication date: August 7, 2014
    Inventors: Luiz Belardinelli, Arvinder Dhalla
  • Method of treating atrial fibrillation
    Patent number: 8754087
    Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: June 17, 2014
    Assignee: Gilead Sciences, Inc.
    Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
  • N-Pyrazole A2A Receptor Agonists
    Publication number: 20140073596
    Abstract: 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Application
    Filed: September 6, 2013
    Publication date: March 13, 2014
    Applicant: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
  • Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using Aadenosine receptor antagonists
    Patent number: 8609671
    Abstract: The invention is related to methods of inhibiting hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: December 17, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Dewan Zeng, Hongyan Zhong
  • METHOD OF TREATING ATRIAL FIBRILLATION
    Publication number: 20130317038
    Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.
    Type: Application
    Filed: May 31, 2013
    Publication date: November 28, 2013
    Applicant: Gilead Sciences, Inc.
    Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
  • N-pyrazole Areceptor agonists
    Patent number: 8569260
    Abstract: The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds to stimulate mammalian coronary vasodilation for imaging the heart.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: October 29, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
  • Methods of myocardial perfusion imaging
    Patent number: 8536150
    Abstract: The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: September 17, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
  • Method of treating atrial fibrillation
    Patent number: 8513254
    Abstract: The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: August 20, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Charles Antzelevitch, Luiz Belardinelli, Alexander Burashnikov, John Shryock, Dewan Zeng
  • Myocardial perfusion imaging methods and compositions
    Patent number: 8470801
    Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: June 25, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Mitchell Rosner
  • Method of preventing and treating airway remodeling and pulmonary inflammation using Aadenosine receptor antagonists
    Patent number: 8466129
    Abstract: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: June 18, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Dewan Zeng, Michael R. Blackburn, Luiz Belardinelli
  • N-PYRAZOLE A2A RECEPTOR AGONISTS
    Publication number: 20130058866
    Abstract: 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Application
    Filed: August 29, 2012
    Publication date: March 7, 2013
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli
  • COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION
    Publication number: 20120269898
    Abstract: Provided are formulations comprising therapeutically effective amounts of ambrisentan or a pharmaceutically acceptable salt thereof and tadalafil or a pharmaceutically acceptable salt thereof and methods of treating and/or preventing pulmonary hypertension by administration of the formulations.
    Type: Application
    Filed: October 14, 2011
    Publication date: October 25, 2012
    Inventors: Luiz Belardinelli, Hunter Campbell Gillies, Faquan Liang, John Shryock, Suya Yang
  • USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS
    Publication number: 20120258974
    Abstract: Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A2B adenosine receptor antagonist.
    Type: Application
    Filed: April 5, 2012
    Publication date: October 11, 2012
    Inventors: Luiz Belardinelli, Hongyan Zhong, Dewan Zeng
  • METHODS OF MYOCARDIAL PERFUSION IMAGING
    Publication number: 20120251440
    Abstract: The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.
    Type: Application
    Filed: June 15, 2012
    Publication date: October 4, 2012
    Applicant: Gilead Sciences, Inc.
    Inventors: Luiz Belardinelli, Brent K. Blackburn, Zhenhai Gao
  • N-pyrazole A2A receptor agonists
    Patent number: 8278435
    Abstract: The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds to stimulate mammalian coronary vasodilation for imaging the heart.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 2, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata Palle, Luiz Belardinelli
  • METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20120220608
    Abstract: The invention is related to methods of preventing and treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 30, 2012
    Inventors: Luiz Belardinelli, Dewan Zeng, Hongyan Zhong
  • MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS
    Publication number: 20120195827
    Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
    Type: Application
    Filed: January 30, 2012
    Publication date: August 2, 2012
    Inventors: Luiz Belardinelli, Mitchell Rosner
  • USE OF A2A ADENOSINE RECEPTOR AGONISTS
    Publication number: 20120189538
    Abstract: Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
    Type: Application
    Filed: December 21, 2011
    Publication date: July 26, 2012
    Inventors: Toufigh Gordi, Ann Walls Olmsted, Hsiao Dee Lieu, Luiz Belardinelli